Clinical trial
Safety and Efficacy Study of ABX-EGF in Patients With Renal Cancer, Part 2
NCT00425035 · Amgen, Industry · Completed
Key facts
| NCT number | NCT00425035 |
|---|---|
| Title | Safety and Efficacy Study of ABX-EGF in Patients With Renal Cancer, Part 2 |
| Official title | A Two-part, Multiple Dose Clinical Trial Evaluating the Safety and Effectiveness of ABX-EGF in Patients With Renal Carcinoma |
| Lead sponsor | Amgen, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Advanced Renal Cell Carcinoma |
| Intervention type | Drug |
| Interventions | Panitumumab (ABX-EGF) |
| Enrollment | 115 |
| Start date | Feb 1, 2003 |
| First posted | Jan 22, 2007 |
| Last update posted | May 13, 2013 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: